ULISSE BIOMED SPA (UBM.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:UBM - IT0005451213 - Common Stock
UBM.MI Key Statistics, Chart & Performance
The current stock price of UBM.MI is 0.8 EUR. In the past month the price decreased by -24.88%. In the past year, price decreased by -68.19%.
UBM.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 67.52 | 43.90B | ||
| 1AE.DE | ARGENX SE | 67.8 | 44.08B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.56B | ||
| 2X1.DE | ABIVAX SA | N/A | 9.39B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.03B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.83B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.85B | ||
| NANO.PA | NANOBIOTIX | N/A | 932.49M | ||
| 5CV.DE | CUREVAC NV | 6.24 | 815.12M | ||
| IVA.PA | INVENTIVA SA | N/A | 744.97M | ||
| PHIL.MI | PHILOGEN SPA | 20.44 | 681.29M | ||
| FYB.DE | FORMYCON AG | N/A | 452.35M |
Related stock screener links
About UBM.MI
Company Profile
Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine and currently employs 23 full-time employees. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
Company Info
ULISSE BIOMED SPA
Via Aquileia 17
Udine UDINE IT
Employees: 22
Phone: 390403757540
ULISSE BIOMED SPA / UBM.MI FAQ
Can you describe the business of ULISSE BIOMED SPA?
Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine and currently employs 23 full-time employees. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.
What is the stock price of ULISSE BIOMED SPA today?
The current stock price of UBM.MI is 0.8 EUR.
Does UBM stock pay dividends?
UBM.MI does not pay a dividend.
What is the ChartMill rating of ULISSE BIOMED SPA stock?
UBM.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of UBM stock?
ULISSE BIOMED SPA (UBM.MI) has a market capitalization of 20.41M EUR. This makes UBM.MI a Nano Cap stock.
UBM.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to UBM.MI. When comparing the yearly performance of all stocks, UBM.MI is a bad performer in the overall market: 95.32% of all stocks are doing better.
UBM.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to UBM.MI. UBM.MI has a bad profitability rating. Also its financial health evaluation is rather negative.
UBM.MI Financial Highlights
Over the last trailing twelve months UBM.MI reported a non-GAAP Earnings per Share(EPS) of -0.2. The EPS increased by 65.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.16% | ||
| ROE | -24.96% | ||
| Debt/Equity | 0.05 |
UBM.MI Forecast & Estimates
5 analysts have analysed UBM.MI and the average price target is 1.52 EUR. This implies a price increase of 89.98% is expected in the next year compared to the current price of 0.8.
For the next year, analysts expect an EPS growth of 84.6% and a revenue growth -19.59% for UBM.MI